Streetbeat News

Products Services

ALGS

Aligos Therapeutics will present data on its liver disease programs at the European Association for the Study of the Liver (EASL) Congress 2023 from June 21-24.

Portfolio Pulse from Benzinga Newsdesk

June 07, 2023 | 11:31 am

ICPT

Intercept Pharmaceuticals announced new data showing the potential of a fixed-dose combination of Obeticholic Acid and Bezafibrate to normalize multiple biomarkers in Primary Biliary Cholangitis.

Portfolio Pulse from Benzinga Newsdesk

June 07, 2023 | 11:20 am

ORGS

Orgenesis has announced a partnership agreement with the University of California system to roll out its Mobile Processing Units and Labs (OMPULs) at medical or academic institutions. This will enable Orgenesis' proprietary point-of-care (POCare) Service Platform to manufacture therapeutics at hospitals throughout California for clinical trials.

Portfolio Pulse from Benzinga Newsdesk

June 07, 2023 | 11:12 am

TNXP

Tonix Pharmaceuticals announced data presentations involving TNX-1500 for the prevention of rejection in kidney and heart allograft transplantation in animal models. TNX-1500 is expected to enter Phase 1 trial in Q3 2023.

Portfolio Pulse from Benzinga Newsdesk

June 07, 2023 | 11:09 am

VTYX

Ventyx Biosciences has completed enrollment for its Phase 2 trials of VTX002 in ulcerative colitis and VTX958 in plaque psoriasis. Topline data for both trials are expected in early Q4 and Q4 2023, respectively.

Portfolio Pulse from Benzinga Newsdesk

June 07, 2023 | 11:06 am

PCRFY

PLTR

Panasonic Energy of North America (PENA) has chosen Palantir Foundry to operationalize data and introduce automated efficiencies in its operations. This partnership aims to improve PENA's manufacturing processes and reduce costs.

Portfolio Pulse from Benzinga Newsdesk

June 07, 2023 | 11:04 am

VTYX

Ventyx Biosciences (NASDAQ:VTYX) has completed patient enrollment for its Phase 2 trials of VTX002 in ulcerative colitis and VTX958 in plaque psoriasis.

Portfolio Pulse from Benzinga Newsdesk

June 07, 2023 | 11:04 am

ABBV

AbbVie has announced that its schizophrenia treatment drug, VRAYLAR, will be reimbursed under the Non-Insured Health Benefits (NIHB) Program. This will make the drug more accessible to patients in need.

Portfolio Pulse from Benzinga Newsdesk

June 07, 2023 | 11:03 am

COYA

Coya Therapeutics (NASDAQ:COYA) reported additional biomarker and brain imaging results from an open-label proof-of-concept clinical study for COYA 301 in patients with mild to moderate Alzheimer's Disease. The results will be presented on June 7th, 2023, at the LD Micro Conference in Los Angeles.

Portfolio Pulse from Benzinga Newsdesk

June 07, 2023 | 11:03 am

FGEN

Fibrogen's Phase 3 Lelantos-1 trial of Pamrevlumab for non-ambulatory patients with Duchenne Muscular Dystrophy failed to meet the primary endpoint of Performance of the Upper Limb 2.0 score at week 52 compared to baseline.

Portfolio Pulse from Benzinga Newsdesk

June 07, 2023 | 10:57 am